# Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer

> **NCT00183898** · PHASE2 · UNKNOWN · sponsor: **University of Southern California** · enrollment: 75 (actual)

## Conditions studied

- Gastric Cancer
- Esophageal Cancer

## Interventions

- **DRUG:** oxaliplatin, capecitabine

## Key facts

- **NCT ID:** NCT00183898
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-12-28
- **Primary completion:** 2013-02-04
- **Final completion:** 2019-12-28
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2019-05-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00183898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00183898, "Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00183898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*